Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,145
Out of 5,055 analysts
38
Total ratings
25%
Success rate
-35.71%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.92 | +1,094.87% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.88 | +136.49% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $1.41 | +419,758.16% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.33 | +1,253.38% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $2.70 | +26,344.44% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.45 | +4,333.61% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.43 | +9,120.84% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.90 | +28,865.52% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $11.35 | +217.18% | 1 | Mar 7, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $4.82 | +373,343.98% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $7.10 | +322.54% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $8.52 | +2,247.42% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $4.21 | +232.54% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $0.90 | +2,402,035.23% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.19 | +572.27% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $3.15 | +3,074.60% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.82 | +48,817.70% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $8.40 | +352.65% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.05 | +4,582.93% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.42 | +815.49% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.92
Upside: +1,094.87%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.88
Upside: +136.49%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $1.41
Upside: +419,758.16%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.33
Upside: +1,253.38%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $2.70
Upside: +26,344.44%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.45
Upside: +4,333.61%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.43
Upside: +9,120.84%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.90
Upside: +28,865.52%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $11.35
Upside: +217.18%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $4.82
Upside: +373,343.98%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $7.10
Upside: +322.54%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $8.52
Upside: +2,247.42%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $4.21
Upside: +232.54%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $0.90
Upside: +2,402,035.23%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.19
Upside: +572.27%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $3.15
Upside: +3,074.60%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.82
Upside: +48,817.70%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $8.40
Upside: +352.65%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.05
Upside: +4,582.93%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.42
Upside: +815.49%